Premium
Application of 3D Mass Spectrometry Imaging to TKIs
Author(s) -
Morosi Lavinia,
Giordano Silvia,
Falcetta Francesca,
Frapolli Roberta,
Licandro Simonetta A.,
Matteo Cristina,
Zucchetti Massimo,
Ubezio Paolo,
Erba Eugenio,
Visentin Sonja,
D'Incalci Maurizio,
Davoli Enrico
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.786
Subject(s) - imatinib , mass spectrometry imaging , mass spectrometry , visualization , tyrosine kinase inhibitor , chemistry , tyrosine kinase , cancer research , computational biology , chromatography , medicine , computer science , biochemistry , biology , data mining , receptor , cancer , myeloid leukemia
Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by MSI provides a more informative description of the tumor drug distribution compared to the high‐performance liquid chromatography method, highlighting the heterogeneity of intratumor drug concentration. This additional information can be important in understanding chemoresistance to target agents. Here, we present the 3D visualization of the tyrosine kinase inhibitor (TKI), imatinib, in a xenograft model of resistant malignant pleural mesothelioma.